Skip to main content
SpringerLink
Log in

Rivaroxaban-related liver injury: Canadian reports

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Health Canada has stated that it is important to include information regarding: drug dose, duration of treatment, relevant patient medical conditions, concomitant medications and dosages, liver biochemistry, exclusion of other potential causes of liver injury, response to drug discontinuation, and patient outcomes.

Reference

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rivaroxaban-related liver injury: Canadian reports. Reactions Weekly 1568, 5 (2015). https://doi.org/10.1007/s40278-015-5063-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-015-5063-z

Search

Navigation